Wearable Solution Articles & Analysis
12 news found
Breakthrough pulse oximetry (SpO2 ) optical sensor solution offers medical-grade accuracy of oxygen level measurement across skin tones and while in motion Patented SpO2 sensor chipset, integrated processing and reference design capability to power the next generation of medical and consumer wearable devices BioIntelliSense, a continuous health monitoring and clinical intelligence company, ...
Modular Medical, Inc. (the "Company" or "Modular Medical")(NASDAQ:MODD) today announced that it has appointed industry veteran Kevin Schmid as its Chief Operating Officer. Mr. Schmid brings extensive operations and business development leadership experience in diabetes and drug delivery. As Vice President of Operations and Business Development at Insulet Corporation, he was instrumental in the ...
Neurolief Ltd., a neurotechnology innovator, today announced enrollment of the first patient in its pivotal clinical study evaluating Relivion® DP for the treatment of major depressive disorder (MDD). The Relivion DP is the first non-invasive, multi-channel brain neuromodulation system for at home treatment of neurological and neuropsychiatric disorders. The trial, MOOD, will assess the ...
Neurolief, an Israel-based company pioneering neuromodulation for the treatment of chronic neurological and neuropsychiatric disorders, and NeuroFront, a clinical stage biotech company focusing on innovative neuroscience therapies, jointly announced an exclusive licensing agreement for NeuroFront to develop and commercialize Relivion, non-invasive medical devices for the treatment of migraine and ...
Neurolief, a neurotechnology innovator, today announced new data released at the 64th Annual Scientific Meeting hosted by the American Headache Society (June 9-12th, 2022, Denver, CO). The real-world, open-label analysis presents clinically meaningful data on the prevention of migraine, including responder rate, reduction in monthly migraine days and reduction in medication use for those with ...
Neurolief, a neurotechnology innovator, today announces the publication of the SP301 study in the Pain and Therapy Journal that demonstrates the safety and efficacy of Relivion MG, Neurolief’s CE-marked and FDA cleared wearable neuromodulation system for at-home treatment of migraine with remote physician monitoring. The study is the first to prove that external concurrent stimulation of ...
The investment will allow Flosonics Medical to scale up the manufacturing and distribution of cutting-edge medical solutions while strengthening the province’s pandemic supply chain Flosonics Medical received over $1.5 million through the province’s Ontario Together Fund to scale up the manufacturing and distribution of FloPatch, the world’s first wearable wireless Doppler ...
Neurolief, an innovator in neurotechnology, announces the company has received Food and Drug Administration (FDA) clearance for its Relivion® system. Relivion® is the first non-invasive multi-channel brain neuromodulation system for at home treatment of acute migraine, a debilitating neurological disease impacting 39 million people and resulting in 1.2 million emergency department visits ...
Neurolief Ltd., a neurotechnology innovator, today announces that it has entered into an exclusive agreement with Sawai Pharmaceutical Co., Ltd. for the development and marketing of Relivion®, a non-invasive digital medical device for migraine and depression, in Japan. Relivion® is a non-invasive brain neuromodulation* device that is placed around the head and delivers unparalleled ...
Neurolief, a neurotechnology innovator, today announces findings of the RIME US pivotal trial that demonstrate the safety and efficacy of the Relivion®, a novel external brain neuromodulation system for self-administered treatment of migraine. The study met all its endpoints with statistical significance. “The results of this study are extremely promising for those seeking an ...
Neurolief, a medical neurotechnology innovator, today announces that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation to the Relivion®DP system, the first non-invasive multi-channel brain neuromodulation technology, for the treatment of major depression. A wearable device, the Relivion®DP system is designed as an adjunctive treatment to pharmaceutical ...
CardiacSense is a leading manufacturer of a range of wearable devices for the continuous monitoring of heart arrhythmias and blood pressure HSC signs exclusive Distribution Agreement for Australia & New Zealand for watches & wristbands HomeStay to integrate CardiacSense solutions in HSC’s IoT Platform for assistive technology HomeStay Care Limited (ASX: HSC) ...